Sponsor Meetings: Better Comportment, Better Understanding Under Watchful Eyes of Neutral Observers?
This article was originally published in RPM Report
Executive Summary
FDA is getting a head start on one item on the PDUFA V to-do list: hiring a contractor to observe and analyze meetings with sponsors during the NDA review process. The presence of a third-party may have an immediate effect on those meetings.
You may also be interested in...
The Most Important Things About PDUFA
Office of New Drugs Director John Jenkins offers his top three list of the most important elements of PDUFA V – and underscores that accountability is a two-way street.
FDA's Great(er) Expectations: Avoiding a Refuse-to-File in a New Review Environment
Each year, FDA rejects just a handful of new drug and biologics applications that aren’t quite complete enough for review. Now the agency’s revamped review process is forcing its staff to take a closer, earlier look at new submissions. Merck’s Zetia/Lipitor "refuse to file" letter is a case in point. Unless things improve, Office of New Drugs Director John Jenkins says, industry can expect more early rejections from FDA.
From Proof of Concept to First-Cycle Approval: Reducing Drug Development Risk Through Effective Meetings with FDA
Effective FDA meetings are a key success factor for speeding up pharmaceutical development, but they must be properly managed to maximize their benefits.